<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00329784</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN032AD</org_study_id>
    <nct_id>NCT00329784</nct_id>
  </id_info>
  <brief_title>Promoting Tolerance to Peanut in High-Risk Children</brief_title>
  <acronym>LEAP</acronym>
  <official_title>Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether early exposure to peanuts promotes tolerance and provides
      protection from developing peanut allergy in children who are allergic to eggs or who have
      severe eczema.

      This study has been continued into the ITN049AD (LEAP-On) Study (NCT01366846).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic reactions to peanuts are potentially life-threatening and, in some children, can
      result from ingestion of only trace quantities of peanuts. At highest risk are children with
      eczema or who are allergic to eggs; these children have a 20% chance of developing peanut
      allergy by the age of five. The majority of children allergic to peanuts have their first
      reaction between the ages of 14 and 24 months, often at the time of their first exposure to
      peanut. Currently, there is no cure for peanut allergy.

      Peanut allergy has become an increasingly common problem in early childhood in the United
      States and the United Kingdom. Despite current public health guidelines in both countries
      recommending the avoidance of peanut consumption in the first years of life, the proportion
      of children with peanut allergy doubled in these countries over the period from 1998 to 2003.
      In contrast, peanuts are commonly consumed by infants in relatively high amounts in Africa,
      Southeast Asia and Israel, yet the rate of peanut allergy is quite low and does not appear to
      be increasing. Peanut consumption by infants in these parts of the world may actually protect
      children from developing peanut allergy by promoting oral tolerance to peanuts.

      Participants in this study will be randomly assigned to either follow a peanut consumption
      regimen or a strict peanut avoidance regimen. Those assigned to the peanut consumption group
      will be asked to consume an age-appropriate snack three times a week for the duration of the
      study and will be monitored closely during their first introduction to peanut.

      Those assigned to the peanut avoidance group will be asked to avoid ingestion of peanut for
      the first three years of life. A physical exam, allergy testing, and other immune system
      tests requiring blood collection will occur at Years 1, 3, and 5 following study entry.
      During the study, parents will maintain regular contact with study dietitians.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Peanut Allergy at 60 Months of Age - by Skin Prick Test Stratum</measure>
    <time_frame>60 months</time_frame>
    <description>At 60 months of age, participants were given an oral food challenge Participants regarded as unlikely to be allergic to peanut received 5 g of peanut protein in a single dose. These participants were considered to have a peanut allergy if they experienced any type of reaction following consumption. A double-blind, placebo-controlled food challenge was offered to other participants with a total of 9.4 g of peanut protein administered in increments. These participants were considered to have a peanut allergy if at any point during the dose escalation procedure the participant had a reaction. Participants for whom data from the oral food challenge were either inconclusive or not available, a diagnostic algorithm based on clinical history, the results of a skin-prick test, and the values for peanut-specific IgE were used to determine whether or not a participant should be considered to have peanut allergy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Peanut Allergy at 60 Months of Age - Both Strata Combined</measure>
    <time_frame>60 months</time_frame>
    <description>At 60 months of age, participants were given an oral food challenge Participants regarded as unlikely to be allergic to peanut received 5 g of peanut protein in a single dose. These participants were considered to have a peanut allergy if they experienced any type of reaction following consumption. A double-blind, placebo-controlled food challenge was offered to other participants with a total of 9.4 g of peanut protein administered in increments. These participants were considered to have a peanut allergy if at any point during the dose escalation procedure the participant had a reaction. Participants for whom data from the oral food challenge were either inconclusive or not available, a diagnostic algorithm based on clinical history, the results of a skin-prick test, and the values for peanut-specific IgE were used to determine whether or not a participant should be considered to have peanut allergy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCORAD at 60 Months</measure>
    <time_frame>60 months</time_frame>
    <description>At 60 months of age, participants were assessed for eczema using a modified Scoring Atopic Dermatitis System (SCORAD). This measure was used to detect eczema in children who may not have had access to topical anti-inflammatory medications or whose parents cannot recall or report the severity of their child's eczema. Eczema is any type of dermatitis or inflammation of the skin. Atopic dermatitis is the most severe and chronic of all types of eczema. The range of the SCORAD is 0-103. A score of 0 indicates no eczema, scores between 0 and 15 indicate mild eczema, scores between 15 and 40 indicate moderate eczema, and scores greater than 40 indicate severe eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Asthma at 60 Months</measure>
    <time_frame>60 months</time_frame>
    <description>At 60 months of age, participants were assessed for asthma. Participants were considered to have asthma if they had a history of cough, wheeze, or shortness of breath that (1) was responsive to therapy with bronchodilators on two or more occasions in the previous 24 months, (2) required one visit to a physician in the previous 24 months, or (3) occurred during the night, during early morning, or upon exercising in the intervals between exacerbations at any time in the previous 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Rhinitis at 60 Months</measure>
    <time_frame>60 months</time_frame>
    <description>At 60 months of age, participants were assessed for rhinitis. Two types of rhinitis were assessed, perennial rhinoconjunctivitis and seasonal rhinoconjunctivitis. Participants were considered to have either type of rhinitis if they showed a sensitization to the allergen and clinical history of rhinoconjunctivitis symptoms experienced either when exposed to the relevant allergen (perennial) or during the relevant season (seasonal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Specific Skin Prick Test Greater Than or Equal to 3mm</measure>
    <time_frame>60 months</time_frame>
    <description>At 60 months of age, participants were assessed for potential allergy to selected food allergens. Participants were considered to have a specific sensitivity if a skin prick containing the allergen produced a wheal size measuring greater than or equal to 3 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Food Specific IgE Greater Than or Equal to 0.35 kU/L</measure>
    <time_frame>60 months</time_frame>
    <description>At 60 months of age, participants were assessed for potential allergy to selected food allergens. Participants were considered to have a specific food sensitivity if a blood draw showed specific IgE levels greater than or equal to 0.35 kU/L for selected ingested allergens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">640</enrollment>
  <condition>Eczema</condition>
  <condition>Egg Allergy</condition>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Peanut Consumption Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants on this arm will consume peanut protein.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peanut Avoidance Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peanut Consumption Group</intervention_name>
    <description>Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.</description>
    <arm_group_label>Peanut Consumption Group</arm_group_label>
    <other_name>Bamba</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to consume solid food

          -  Allergy to eggs and/or severe eczema

          -  Informed consent obtained from parent or guardian.

        Exclusion Criteria:

          -  Clinically significant chronic illness. Participants with eczema or recurrent wheeze
             are not excluded.

          -  Positive skin prick test for peanut allergen with a wheel diameter greater than 4 mm
             in the presence of a negative saline control

          -  Previous or current consumption of peanut protein that exceeds 0.2 g of peanut protein
             on at least one occasion or 0.5 g over a single week

          -  Investigator-suspected allergy to peanut protein

          -  Investigator-suspected allergy to peanut protein in care provider or current household
             member.

          -  Diagnosis of persistent asthma

          -  ALT (SGPT) or bilirubin greater than 2 times the upper limit of age-related normal
             value

          -  BUN or creatinine greater than 1.25 times the upper limit of age-related normal value

          -  Platelet count less than 100,000/mL, hemoglobin less than 9 g/dL, or
             investigator-suspected immunocompromise

          -  Unwillingness or inability to comply with study requirements and procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>10 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gideon Lack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College, St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evelina Children's Hospital, Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network website</description>
  </link>
  <link>
    <url>http://www.leapstudy.co.uk</url>
    <description>LEAP Study informational website</description>
  </link>
  <reference>
    <citation>Palmer K, Burks W. Current developments in peanut allergy. Curr Opin Allergy Clin Immunol. 2006 Jun;6(3):202-6. Review.</citation>
    <PMID>16670515</PMID>
  </reference>
  <reference>
    <citation>Santos AF, Du Toit G, Lack G. Is the use of epinephrine a good marker of severity of allergic reactions during oral food challenges? J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):429-30. doi: 10.1016/j.jaip.2014.12.009.</citation>
    <PMID>25956314</PMID>
  </reference>
  <reference>
    <citation>Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, Brough HA, Santos AF, Harris KM, Radulovic S, Basting M, Turcanu V, Plaut M, Lack G; Immune Tolerance Network LEAP-On Study Team. Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. N Engl J Med. 2016 Apr 14;374(15):1435-43. doi: 10.1056/NEJMoa1514209. Epub 2016 Mar 4.</citation>
    <PMID>26942922</PMID>
  </reference>
  <results_reference>
    <citation>Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, Brough HA, Phippard D, Basting M, Feeney M, Turcanu V, Sever ML, Gomez Lorenzo M, Plaut M, Lack G; LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015 Feb 26;372(9):803-13. doi: 10.1056/NEJMoa1414850. Epub 2015 Feb 23. Erratum in: N Engl J Med. 2016 Jul 28;375(4):398.</citation>
    <PMID>25705822</PMID>
  </results_reference>
  <results_reference>
    <citation>Gruchalla RS, Sampson HA. Preventing peanut allergy through early consumption--ready for prime time? N Engl J Med. 2015 Feb 26;372(9):875-7. doi: 10.1056/NEJMe1500186. Epub 2015 Feb 23.</citation>
    <PMID>25705823</PMID>
  </results_reference>
  <results_reference>
    <citation>Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, Radulovic S, Chan S, Fox A, Turcanu V, Lack G; Learning Early About Peanut Allergy (LEAP) Study Team. Identifying infants at high risk of peanut allergy: the Learning Early About Peanut Allergy (LEAP) screening study. J Allergy Clin Immunol. 2013 Jan;131(1):135-43.e1-12. doi: 10.1016/j.jaci.2012.09.015. Epub 2012 Nov 19.</citation>
    <PMID>23174658</PMID>
  </results_reference>
  <results_reference>
    <citation>Feeney M, Du Toit G, Roberts G, Sayre PH, Lawson K, Bahnson HT, Sever ML, Radulovic S, Plaut M, Lack G; Immune Tolerance Network LEAP Study Team. Impact of peanut consumption in the LEAP Study: Feasibility, growth, and nutrition. J Allergy Clin Immunol. 2016 Oct;138(4):1108-1118. doi: 10.1016/j.jaci.2016.04.016. Epub 2016 Jun 10.</citation>
    <PMID>27297994</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2006</study_first_submitted>
  <study_first_submitted_qc>May 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2006</study_first_posted>
  <results_first_submitted>November 1, 2016</results_first_submitted>
  <results_first_submitted_qc>November 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2016</results_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peanut allergy</keyword>
  <keyword>egg allergy</keyword>
  <keyword>eczema</keyword>
  <keyword>peanut</keyword>
  <keyword>allergy</keyword>
  <keyword>allergies</keyword>
  <keyword>allergic reaction</keyword>
  <keyword>anaphylaxis</keyword>
  <keyword>infants</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Egg Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>SDY660</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY660</doc_url>
      <doc_comment>ImmPort study identifier is SDY660</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SDY660</doc_id>
      <doc_type>Study summary, -design, -adverse event(s), -demographics, -study files</doc_type>
      <doc_url>http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY660</doc_url>
      <doc_comment>ImmPort study identifier is SDY660</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LEAP (ITN032AD)</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.itntrialshare.org/project/Studies/ITN032ADNEJM/Study%20Data/begin.view?pageId=study.PARTICIPANTS</doc_url>
      <doc_comment>TrialShare study identifier is LEAP (ITN032AD)</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>LEAP (ITN032AD)</doc_id>
      <doc_type>Overview, Date &amp; Reports, Manuscripts et al.</doc_type>
      <doc_url>https://www.itntrialshare.org/project/Studies/ITN032ADNEJM/Study%20Data/begin.view?</doc_url>
      <doc_comment>TrialShare study identifier is LEAP (ITN032AD)</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants between 4 and 11 months of age with pre-existing allergy to egg and/or severe eczema were recruited in the United Kingdom between December 2006 and May 2009.</recruitment_details>
      <pre_assignment_details>Participants were stratified into cohorts based on a skin prick test for peanut allergen. Participants were either negative (no measureable wheal after test) or positive (a wheal measuring between 1 and 4 mm in diameter). Participants were then randomized into treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Negative Stratum - Peanut Avoidance Group</title>
          <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
        </group>
        <group group_id="P2">
          <title>Negative Stratum - Peanut Consumption Group</title>
          <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
        </group>
        <group group_id="P3">
          <title>Positive Stratum - Peanut Avoidance Group</title>
          <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
        </group>
        <group group_id="P4">
          <title>Positive Stratum - Peanut Consumption Group</title>
          <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="272"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="267"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>Negative Stratum - Peanut Avoidance Group</title>
          <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
        </group>
        <group group_id="B2">
          <title>Negative Stratum - Peanut Consumption Group</title>
          <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
        </group>
        <group group_id="B3">
          <title>Positive Stratum - Peanut Avoidance Group</title>
          <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
        </group>
        <group group_id="B4">
          <title>Positive Stratum - Peanut Consumption Group</title>
          <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="270"/>
            <count group_id="B2" value="272"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="47"/>
            <count group_id="B5" value="640"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="1.7"/>
                    <measurement group_id="B2" value="7.7" spread="1.8"/>
                    <measurement group_id="B3" value="8.4" spread="1.7"/>
                    <measurement group_id="B4" value="7.9" spread="1.6"/>
                    <measurement group_id="B5" value="7.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="256"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severe Eczema</title>
          <description>Number of participants with severe eczema at baseline. Eczema is any type of dermatitis or inflammation of the skin. Severe eczema for this trial is based on three criteria. The first criterion was the parent or guardians’ description of their child’s eczema severity. The second criterion was the use of topical creams or ointments containing corticosteroids or calcineurin inhibitors. The third criterion will be a modified Scoring Atopic Dermatitis System (SCORAD). Infants with severe eczema are at a high risk of developing a peanut allergy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Onset of Eczema</title>
          <description>Age in months at which eczema symptoms began. Eczema is any type of dermatitis or inflammation of the skin. Severe eczema for this trial is based on three criteria. The first criterion was the parent or guardians’ description of their child’s eczema severity. The second criterion was the use of topical creams or ointments containing corticosteroids or calcineurin inhibitors. The third criterion will be a modified Scoring Atopic Dermatitis System (SCORAD). Infants with severe eczema are at a high risk of developing a peanut allergy</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="1.7"/>
                    <measurement group_id="B2" value="2.3" spread="1.6"/>
                    <measurement group_id="B3" value="2.1" spread="1.6"/>
                    <measurement group_id="B4" value="2.4" spread="1.5"/>
                    <measurement group_id="B5" value="2.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SCORAD</title>
          <description>A modified Scoring Atopic Dermatitis System (SCORAD) was used to detect eczema in children who may not have had access to topical anti-inflammatory medications or whose parents cannot recall or report the severity of their child’s eczema. Eczema is any type of dermatitis or inflammation of the skin. Atopic dermatitis is the most severe and chronic of all types of eczema. The range of the SCORAD is 0-103. Scores less than 15 indicate mild eczema, scores between 15 and 40 indicate moderate eczema, and scores greater than 40 indicate severe eczema.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" spread="19.9"/>
                    <measurement group_id="B2" value="33.3" spread="18.4"/>
                    <measurement group_id="B3" value="33.7" spread="16.2"/>
                    <measurement group_id="B4" value="37.8" spread="18.6"/>
                    <measurement group_id="B5" value="34.4" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total IgE</title>
          <description>Total Immunoglobulin E (IgE) includes the following potential allergens: peanut, hen’s egg white, cow’s milk, sesame, brazil nut, hazel nut, cashew, almond, walnut, house dust mite, cat dander, dog dander, timothy grass pollen, alternaria mold, and birch tree pollen. IgE is measured in a serum sample. Results &lt;75 kUA/L suggests that the participant is not allergic to any of the potential allergens. A result &gt;75 kUA/L suggests at least a mild clinical allergy. The higher the total IgE present in the serum sample, the more likely it is to be a presence of an allergy to at least one allergen</description>
          <units>kUA/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.1" spread="321.8"/>
                    <measurement group_id="B2" value="76.4" spread="181.4"/>
                    <measurement group_id="B3" value="125.7" spread="174.8"/>
                    <measurement group_id="B4" value="306.4" spread="666.5"/>
                    <measurement group_id="B5" value="104.8" spread="307.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peanut-specific IgE</title>
          <description>Immunoglobulin E (IgE) is an antibody produced by the immune system. If you have an allergy, your immune system overreacts to an allergen by producing antibodies called IgE. These antibodies travel to cells that release chemicals, causing an allergic reaction. Peanut-specific IgE is measured in a serum sample following a peanut skin prick test. Results &lt;0.35 kUA/L is considered low level allergic reaction to peanut. Results from &gt;= 0.35 to &lt;15 kUA/L are considered mid-level allergic reaction to peanut. Results &gt;=15 kUA/L are considered high level allergic reaction to peanut.</description>
          <units>kUA/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="B2" value="0.0" lower_limit="0.0" upper_limit="0.1"/>
                    <measurement group_id="B3" value="0.4" lower_limit="0.1" upper_limit="3.0"/>
                    <measurement group_id="B4" value="1.3" lower_limit="0.2" upper_limit="5.5"/>
                    <measurement group_id="B5" value="0.0" lower_limit="0.0" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Peanut Allergy at 60 Months of Age – by Skin Prick Test Stratum</title>
        <description>At 60 months of age, participants were given an oral food challenge Participants regarded as unlikely to be allergic to peanut received 5 g of peanut protein in a single dose. These participants were considered to have a peanut allergy if they experienced any type of reaction following consumption. A double-blind, placebo-controlled food challenge was offered to other participants with a total of 9.4 g of peanut protein administered in increments. These participants were considered to have a peanut allergy if at any point during the dose escalation procedure the participant had a reaction. Participants for whom data from the oral food challenge were either inconclusive or not available, a diagnostic algorithm based on clinical history, the results of a skin-prick test, and the values for peanut-specific IgE were used to determine whether or not a participant should be considered to have peanut allergy.</description>
        <time_frame>60 months</time_frame>
        <population>Intent-to-treat – all randomly assigned participants who were evaluable for peanut allergy at age 60 months</population>
        <group_list>
          <group group_id="O1">
            <title>Negative Stratum - Peanut Avoidance Group</title>
            <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O2">
            <title>Negative Stratum - Peanut Consumption Group</title>
            <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
          <group group_id="O3">
            <title>Positive Stratum - Peanut Avoidance Group</title>
            <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O4">
            <title>Positive Stratum - Peanut Consumption Group</title>
            <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peanut Allergy at 60 Months of Age – by Skin Prick Test Stratum</title>
          <description>At 60 months of age, participants were given an oral food challenge Participants regarded as unlikely to be allergic to peanut received 5 g of peanut protein in a single dose. These participants were considered to have a peanut allergy if they experienced any type of reaction following consumption. A double-blind, placebo-controlled food challenge was offered to other participants with a total of 9.4 g of peanut protein administered in increments. These participants were considered to have a peanut allergy if at any point during the dose escalation procedure the participant had a reaction. Participants for whom data from the oral food challenge were either inconclusive or not available, a diagnostic algorithm based on clinical history, the results of a skin-prick test, and the values for peanut-specific IgE were used to determine whether or not a participant should be considered to have peanut allergy.</description>
          <population>Intent-to-treat – all randomly assigned participants who were evaluable for peanut allergy at age 60 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Peanut Allergy at 60 Months of Age – Both Strata Combined</title>
        <description>At 60 months of age, participants were given an oral food challenge Participants regarded as unlikely to be allergic to peanut received 5 g of peanut protein in a single dose. These participants were considered to have a peanut allergy if they experienced any type of reaction following consumption. A double-blind, placebo-controlled food challenge was offered to other participants with a total of 9.4 g of peanut protein administered in increments. These participants were considered to have a peanut allergy if at any point during the dose escalation procedure the participant had a reaction. Participants for whom data from the oral food challenge were either inconclusive or not available, a diagnostic algorithm based on clinical history, the results of a skin-prick test, and the values for peanut-specific IgE were used to determine whether or not a participant should be considered to have peanut allergy.</description>
        <time_frame>60 months</time_frame>
        <population>Intent-to-treat – all randomly assigned participants who were evaluable for peanut allergy at age 60 months</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Avoidance Group</title>
            <description>Participants assigned to the peanut avoidance group were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Consumption Group</title>
            <description>Participants assigned to the peanut consumption group were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Peanut Allergy at 60 Months of Age – Both Strata Combined</title>
          <description>At 60 months of age, participants were given an oral food challenge Participants regarded as unlikely to be allergic to peanut received 5 g of peanut protein in a single dose. These participants were considered to have a peanut allergy if they experienced any type of reaction following consumption. A double-blind, placebo-controlled food challenge was offered to other participants with a total of 9.4 g of peanut protein administered in increments. These participants were considered to have a peanut allergy if at any point during the dose escalation procedure the participant had a reaction. Participants for whom data from the oral food challenge were either inconclusive or not available, a diagnostic algorithm based on clinical history, the results of a skin-prick test, and the values for peanut-specific IgE were used to determine whether or not a participant should be considered to have peanut allergy.</description>
          <population>Intent-to-treat – all randomly assigned participants who were evaluable for peanut allergy at age 60 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCORAD at 60 Months</title>
        <description>At 60 months of age, participants were assessed for eczema using a modified Scoring Atopic Dermatitis System (SCORAD). This measure was used to detect eczema in children who may not have had access to topical anti-inflammatory medications or whose parents cannot recall or report the severity of their child’s eczema. Eczema is any type of dermatitis or inflammation of the skin. Atopic dermatitis is the most severe and chronic of all types of eczema. The range of the SCORAD is 0-103. A score of 0 indicates no eczema, scores between 0 and 15 indicate mild eczema, scores between 15 and 40 indicate moderate eczema, and scores greater than 40 indicate severe eczema.</description>
        <time_frame>60 months</time_frame>
        <population>Intent-to-treat with SCORAD data available</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Avoidance Group</title>
            <description>Participants assigned to the peanut avoidance group were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Consumption Group</title>
            <description>Participants assigned to the peanut consumption group were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
        </group_list>
        <measure>
          <title>SCORAD at 60 Months</title>
          <description>At 60 months of age, participants were assessed for eczema using a modified Scoring Atopic Dermatitis System (SCORAD). This measure was used to detect eczema in children who may not have had access to topical anti-inflammatory medications or whose parents cannot recall or report the severity of their child’s eczema. Eczema is any type of dermatitis or inflammation of the skin. Atopic dermatitis is the most severe and chronic of all types of eczema. The range of the SCORAD is 0-103. A score of 0 indicates no eczema, scores between 0 and 15 indicate mild eczema, scores between 15 and 40 indicate moderate eczema, and scores greater than 40 indicate severe eczema.</description>
          <population>Intent-to-treat with SCORAD data available</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="11.6"/>
                    <measurement group_id="O2" value="6.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.369</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Asthma at 60 Months</title>
        <description>At 60 months of age, participants were assessed for asthma. Participants were considered to have asthma if they had a history of cough, wheeze, or shortness of breath that (1) was responsive to therapy with bronchodilators on two or more occasions in the previous 24 months, (2) required one visit to a physician in the previous 24 months, or (3) occurred during the night, during early morning, or upon exercising in the intervals between exacerbations at any time in the previous 12 months.</description>
        <time_frame>60 months</time_frame>
        <population>Intent-to-treat with asthma data available</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Avoidance Group</title>
            <description>Participants assigned to the peanut avoidance group were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Consumption Group</title>
            <description>Participants assigned to the peanut consumption group were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Asthma at 60 Months</title>
          <description>At 60 months of age, participants were assessed for asthma. Participants were considered to have asthma if they had a history of cough, wheeze, or shortness of breath that (1) was responsive to therapy with bronchodilators on two or more occasions in the previous 24 months, (2) required one visit to a physician in the previous 24 months, or (3) occurred during the night, during early morning, or upon exercising in the intervals between exacerbations at any time in the previous 12 months.</description>
          <population>Intent-to-treat with asthma data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.642</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Rhinitis at 60 Months</title>
        <description>At 60 months of age, participants were assessed for rhinitis. Two types of rhinitis were assessed, perennial rhinoconjunctivitis and seasonal rhinoconjunctivitis. Participants were considered to have either type of rhinitis if they showed a sensitization to the allergen and clinical history of rhinoconjunctivitis symptoms experienced either when exposed to the relevant allergen (perennial) or during the relevant season (seasonal).</description>
        <time_frame>60 months</time_frame>
        <population>Intent-to-treat with rhinitis data available</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Avoidance Group</title>
            <description>Participants assigned to the peanut avoidance group were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Consumption Group</title>
            <description>Participants assigned to the peanut consumption group were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rhinitis at 60 Months</title>
          <description>At 60 months of age, participants were assessed for rhinitis. Two types of rhinitis were assessed, perennial rhinoconjunctivitis and seasonal rhinoconjunctivitis. Participants were considered to have either type of rhinitis if they showed a sensitization to the allergen and clinical history of rhinoconjunctivitis symptoms experienced either when exposed to the relevant allergen (perennial) or during the relevant season (seasonal).</description>
          <population>Intent-to-treat with rhinitis data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="315"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seasonal Rhinoconjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perennial Rhinoconjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Seasonal Rhinoconjunctivitis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.417</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Perennial Rhinoconjunctivitis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.926</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Specific Skin Prick Test Greater Than or Equal to 3mm</title>
        <description>At 60 months of age, participants were assessed for potential allergy to selected food allergens. Participants were considered to have a specific sensitivity if a skin prick containing the allergen produced a wheal size measuring greater than or equal to 3 mm.</description>
        <time_frame>60 months</time_frame>
        <population>Intent-to-treat with data available</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Avoidance Group</title>
            <description>Participants assigned to the peanut avoidance group were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Consumption Group</title>
            <description>Participants assigned to the peanut consumption group were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Specific Skin Prick Test Greater Than or Equal to 3mm</title>
          <description>At 60 months of age, participants were assessed for potential allergy to selected food allergens. Participants were considered to have a specific sensitivity if a skin prick containing the allergen produced a wheal size measuring greater than or equal to 3 mm.</description>
          <population>Intent-to-treat with data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peanut Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="316"/>
                    <count group_id="O2" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egg Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="311"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Milk Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sesame Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil nut Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hazel nut Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cashew Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walnut Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Almond Wheal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Peanut Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Egg Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Milk Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.760</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Sesame Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.834</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Brazil Nut Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.882</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Hazel Nut Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Cashew Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Walnut Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Almond Wheal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Food Specific IgE Greater Than or Equal to 0.35 kU/L</title>
        <description>At 60 months of age, participants were assessed for potential allergy to selected food allergens. Participants were considered to have a specific food sensitivity if a blood draw showed specific IgE levels greater than or equal to 0.35 kU/L for selected ingested allergens.</description>
        <time_frame>60 months</time_frame>
        <population>Intent-to-treat with data available</population>
        <group_list>
          <group group_id="O1">
            <title>Peanut Avoidance Group</title>
            <description>Participants assigned to the peanut avoidance group were instructed to avoid exposure to peanut protein during study participation.</description>
          </group>
          <group group_id="O2">
            <title>Peanut Consumption Group</title>
            <description>Participants assigned to the peanut consumption group were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Food Specific IgE Greater Than or Equal to 0.35 kU/L</title>
          <description>At 60 months of age, participants were assessed for potential allergy to selected food allergens. Participants were considered to have a specific food sensitivity if a blood draw showed specific IgE levels greater than or equal to 0.35 kU/L for selected ingested allergens.</description>
          <population>Intent-to-treat with data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peanut IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egg IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Milk IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sesame IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil nut IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hazel nut IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cashew IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walnut IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Almond IgE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="307"/>
                    <count group_id="O2" value="296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Peanut IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.859</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Egg IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.885</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Milk IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Sesame IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Brazil Nut IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Hazel Nut IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Cashew IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Walnut IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for Almond IgE</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.262</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrollment through last study visit (up to five years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Negative Stratum - Peanut Avoidance Group</title>
          <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
        </group>
        <group group_id="E2">
          <title>Negative Stratum - Peanut Consumption Group</title>
          <description>Participants who had a negative response to a skin prick test for peanut allergen (no measurable wheal) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
        </group>
        <group group_id="E3">
          <title>Positive Stratum - Peanut Avoidance Group</title>
          <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut avoidance group. Participants were instructed to avoid exposure to peanut protein during study participation.</description>
        </group>
        <group group_id="E4">
          <title>Positive Stratum - Peanut Consumption Group</title>
          <description>Participants who had a positive response to a skin prick test for peanut allergen (a wheal measuring between 1 and 4 mm) and were then randomized to the peanut consumption group. Participants were fed at least 2 g of peanut protein 3 times per week (a total of 6g). The preferred peanut source was Bamba (a peanut snack), although peanut butter was an acceptable substitute. After age 3, participants were allowed to eat whole peanuts.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Meningococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="270"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="272"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="270"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="272"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="85" subjects_affected="70" subjects_at_risk="270"/>
                <counts group_id="E2" events="48" subjects_affected="45" subjects_at_risk="272"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="270"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="272"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="64" subjects_affected="60" subjects_at_risk="270"/>
                <counts group_id="E2" events="80" subjects_affected="60" subjects_at_risk="272"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="76" subjects_affected="62" subjects_at_risk="270"/>
                <counts group_id="E2" events="100" subjects_affected="70" subjects_at_risk="272"/>
                <counts group_id="E3" events="16" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="97" subjects_affected="71" subjects_at_risk="270"/>
                <counts group_id="E2" events="110" subjects_affected="87" subjects_at_risk="272"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="299" subjects_affected="125" subjects_at_risk="270"/>
                <counts group_id="E2" events="286" subjects_affected="132" subjects_at_risk="272"/>
                <counts group_id="E3" events="98" subjects_affected="38" subjects_at_risk="51"/>
                <counts group_id="E4" events="95" subjects_affected="29" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="270"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="272"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" events="59" subjects_affected="31" subjects_at_risk="270"/>
                <counts group_id="E2" events="47" subjects_affected="29" subjects_at_risk="272"/>
                <counts group_id="E3" events="33" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E4" events="21" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="49" subjects_affected="39" subjects_at_risk="270"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="272"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="142" subjects_affected="84" subjects_at_risk="270"/>
                <counts group_id="E2" events="136" subjects_affected="89" subjects_at_risk="272"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E4" events="22" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" events="55" subjects_affected="41" subjects_at_risk="270"/>
                <counts group_id="E2" events="31" subjects_affected="20" subjects_at_risk="272"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="227" subjects_affected="139" subjects_at_risk="270"/>
                <counts group_id="E2" events="308" subjects_affected="173" subjects_at_risk="272"/>
                <counts group_id="E3" events="44" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E4" events="37" subjects_affected="27" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="272"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="164" subjects_affected="98" subjects_at_risk="270"/>
                <counts group_id="E2" events="134" subjects_affected="83" subjects_at_risk="272"/>
                <counts group_id="E3" events="32" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E4" events="30" subjects_affected="20" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="91" subjects_affected="74" subjects_at_risk="270"/>
                <counts group_id="E2" events="112" subjects_affected="86" subjects_at_risk="272"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="270"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="272"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="270"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="272"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="164" subjects_affected="146" subjects_at_risk="270"/>
                <counts group_id="E2" events="166" subjects_affected="144" subjects_at_risk="272"/>
                <counts group_id="E3" events="42" subjects_affected="38" subjects_at_risk="51"/>
                <counts group_id="E4" events="38" subjects_affected="33" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="67" subjects_affected="46" subjects_at_risk="270"/>
                <counts group_id="E2" events="79" subjects_affected="53" subjects_at_risk="272"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" events="19" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="282" subjects_affected="160" subjects_at_risk="270"/>
                <counts group_id="E2" events="399" subjects_affected="191" subjects_at_risk="272"/>
                <counts group_id="E3" events="53" subjects_affected="26" subjects_at_risk="51"/>
                <counts group_id="E4" events="71" subjects_affected="31" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="121" subjects_affected="119" subjects_at_risk="270"/>
                <counts group_id="E2" events="153" subjects_affected="145" subjects_at_risk="272"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="51"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="48" subjects_affected="44" subjects_at_risk="270"/>
                <counts group_id="E2" events="67" subjects_affected="56" subjects_at_risk="272"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="270"/>
                <counts group_id="E2" events="38" subjects_affected="33" subjects_at_risk="272"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="81" subjects_affected="60" subjects_at_risk="270"/>
                <counts group_id="E2" events="121" subjects_affected="68" subjects_at_risk="272"/>
                <counts group_id="E3" events="25" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E4" events="27" subjects_affected="17" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="70" subjects_affected="60" subjects_at_risk="270"/>
                <counts group_id="E2" events="61" subjects_affected="52" subjects_at_risk="272"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" events="16" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="111" subjects_affected="65" subjects_at_risk="270"/>
                <counts group_id="E2" events="111" subjects_affected="58" subjects_at_risk="272"/>
                <counts group_id="E3" events="44" subjects_affected="18" subjects_at_risk="51"/>
                <counts group_id="E4" events="33" subjects_affected="15" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="248" subjects_affected="141" subjects_at_risk="270"/>
                <counts group_id="E2" events="243" subjects_affected="147" subjects_at_risk="272"/>
                <counts group_id="E3" events="45" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E4" events="57" subjects_affected="27" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="48" subjects_affected="39" subjects_at_risk="270"/>
                <counts group_id="E2" events="41" subjects_affected="34" subjects_at_risk="272"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="54" subjects_affected="31" subjects_at_risk="270"/>
                <counts group_id="E2" events="78" subjects_affected="54" subjects_at_risk="272"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E4" events="23" subjects_affected="17" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research Operations Program</name_or_title>
      <organization>DAIT/NIAID</organization>
      <phone>301-594-7669</phone>
      <email>DAITClinicalTrialsGov@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

